Serum S-100B protein monitoring in patients with severe traumatic brain injury.

Autor: Korfias, Stefanos, Stranjalis, George, Boviatsis, Efstathios, Psachoulia, Christina, Jullien, Gerard, Gregson, Barbara, Mendelow, A. David, Sakas, Damianos E.
Předmět:
Zdroj: Intensive Care Medicine; Feb2007, Vol. 33 Issue 2, p255-260, 6p, 8 Black and White Photographs, 1 Chart, 8 Graphs
Abstrakt: Objective: S-100B protein is a promising marker of injury severity and outcome after head injury. We examined the relationship between serum S-100B concentrations and injury severity, clinical course, survival, and treatment efficacy after severe traumatic brain injury (TBI).Design and Setting: Prospective observational study in a neurosurgical intensive care unit.Patients and Participants: 102 adult patients with severe TBI, admitted between June 2001 and November 2003 (30 months).Interventions: Serum S-100B levels were measured by immunoluminometric technique on admission and every 24 h thereafter for a maximum of 7 days.Measurements and Results: Initial S-100B levels were significantly related to pupillary status, computed tomography severity 1, and 1-month survival. Cox's proportional hazard regression analysis showed that initial S-100B was an independent predictor of 1-month survival, in the presence of dilated pupils, and with increased age. Subjects with initial levels above 1 microg/l had a nearly threefold increased probability of death within 1 month. Serum S-100B alteration indicated neurological improvement or deterioration. Finally, surgical treatment reduced S-100B levels.Conclusions: Serum S-100B protein reflects injury severity and improves prediction of outcome after severe TBI. S-100B may also have a role in assessing the efficacy of treatment after severe TBI. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: